1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,400 | 2,700 | 21.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.01. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON PROGRESS OF THE INCREASE IN SHAREHOLDING ... | 1 | HKEx | ||
| 29.12.25 | JUNSHI BIO (01877): ANNOUNCEMENT - ADJUSTMENTS TO THE EXPECTED TIMETABLE FOR THE UTILIZATION OF PROCEEDS FROM THE 2022 ISSUANCE OF A SHARES | 1 | HKEx | ||
| 18.12.25 | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE PLAN FOR THE REDUCTION IN THE SHAREHOLDING ... | 1 | HKEx | ||
| 10.12.25 | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON PROGRESS OF THE INCREASE IN SHAREHOLDING ... | 1 | HKEx | ||
| 06.12.25 | Junshi Biosciences: Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients | 518 | GlobeNewswire (Europe) | Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R/M NPC, achieving... ► Artikel lesen | |
| 05.12.25 | Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis | 358 | GlobeNewswire (Europe) | SHANGHAI, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 05.12.25 | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE NEW DRUG APPLICATION FOR ROCONKIBART INJECTION | 2 | HKEx | ||
| SHANGHAI JUNSHI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 04.12.25 | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE RESULT OF THE REDUCTION IN SHAREHOLDING ... | - | HKEx | ||
| 03.12.25 | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* INDICATIVE ANNOUNCEMENT ON THE CHANGE IN EQUITY OF THE SHAREHOLDERS ... | 1 | HKEx | ||
| 27.11.25 | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON CASH MANAGEMENT BY USING TEMPORARILY IDLE ... | - | HKEx | ||
| 25.11.25 | Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC | 390 | GlobeNewswire (Europe) | SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 24.11.25 | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF JS001SC FOR THE FIRST-LINE TREATMENT OF NON-SQUAMOUS NSCLC MET PRIMARY ENDPOINTS | - | HKEx | ||
| 14.11.25 | JUNSHI BIO (01877): COMPLETION OF REGISTRATION OF THE FIRST GRANT OF A SHARE OPTIONS UNDER THE 2025 A SHARE OPTION INCENTIVE SCHEME | - | HKEx | ||
| 10.11.25 | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON PROGRESS OF THE INCREASE IN SHAREHOLDING ... | 1 | HKEx | ||
| 28.10.25 | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 2025 THIRD QUARTERLY REPORT | 1 | HKEx | ||
| 22.10.25 | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - WHOLLY-OWNED SUBSIDIARY PASSING FDA ON-SITE INSPECTION | 2 | HKEx | ||
| 21.10.25 | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE CONVENING OF THE 2025 THIRD QUARTERLY ... | 1 | HKEx | ||
| 17.10.25 | Junshi Biosciences gets FDA approval for lung cancer trial | 2 | Investing.com | ||
| 17.10.25 | Junshi Biosciences Announces FDA's Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients | 441 | GlobeNewswire (Europe) | SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 16.10.25 | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - FDA APPROVAL OF INVESTIGATIONAL NEW DRUG APPLICATION FOR PHASE II/III CLINICAL STUDY OF JS207 FOR THE NEOADJUVANT ... | - | HKEx |
1 2 3 4 Weiter >>
68 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 46,250 | -3,65 % | Schlägt Thermo Fisher zu?: Qiagen: Übernahmegerüchte schicken die Aktie auf Kursachterbahn | © Foto: Rafael Henrique - picture allianceÜbernahmegerüchte um den Diagnostikspezialisten Qiagen sorgten am Dienstag für einen rekordverdächtigen Kursanstieg. Am Mittwoch kommt die Aktie wieder etwas... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 93,79 | +3,04 % | Guggenheim raises Structure Therapeutics stock price target to $140 on obesity drug confidence | ||
| CG ONCOLOGY | 57,13 | +4,46 % | What Analysts Are Saying About CG Oncology Stock | ||
| COGENT BIOSCIENCES | 39,900 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| BIONTECH | 100,90 | -0,10 % | Neue Zölle für AMD, OpenAI kauft bei der Konkurrenz von Nvidia, Rheinmetall weiter im Aufwind und BioNTech schürt neue Hoffnung | Die Börsen bleiben weiterhin geprägt von hohen Kursständen, wenngleich es hier und dort auch etwas Gegenwind zu verzeichnen gibt. Nicht jede vielbeachtete Aktie kann derzeit schon neue Rekorde schreiben.... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,64 | +0,23 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ALUMIS | 26,680 | 0,00 % | Chardan Capital initiates coverage on Alumis stock with Buy rating | ||
| PRAXIS PRECISION MEDICINES | 312,60 | -3,54 % | Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus | ||
| KYMERA THERAPEUTICS | 70,74 | 0,00 % | Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (25 Ratings) | ||
| BEAM THERAPEUTICS | 31,120 | 0,00 % | Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway | ||
| KINIKSA PHARMACEUTICALS | 41,830 | +1,95 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Provides Corporate Update | - ARCALYST- (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth -- ARCALYST 2026 net product revenue expected to be $900 - $920 million --... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,850 | 0,00 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| ERASCA | 10,050 | 0,00 % | Erasca, Inc.: Erasca Announces Proposed Public Offering of $150 Million of Common Stock | SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| VERA THERAPEUTICS | 45,770 | +2,10 % | Cantor Fitzgerald reiterates Overweight rating on Vera Therapeutics stock | ||
| IMMUNOME | 24,870 | +4,15 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung |
SHANGHAI JUNSHI BIOSCIENCES CO LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,180 (+7,44 %) liegt der Kurs bei 2,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI JUNSHI BIOSCIENCES CO LTD finden Sie auf Wallstreet Online.